Collegium Pharmaceutical, Inc. (COLL)

Collegium Pharmaceutical, Inc. experienced several notable stock events between July 2025 and January 2026. On October 13, 2025, Collegium celebrated its 10-year anniversary as a publicly traded company. On November 6, 2025, the company released its Q3 2025 earnings, surpassing analyst estimates and raising its full-year 2025 guidance, with the stock hitting a new 52-week high. In December 2025, Collegium closed a $980 million syndicated credit facility. On December 29, 2025, the stock reached an all-time high. On January 8, 2026, Collegium announced its full-year 2026 financial guidance. Overall, the stock price increased significantly between December 2024 and December 2025.

Demand for Collegium Pharmaceutical, Inc.'s products exhibits some seasonality. Jornay PM, the company's ADHD medication, experienced accelerated prescription growth during the critical back-to-school season, suggesting a potential increase in demand during periods when school is in session.

Collegium Pharmaceutical, Inc. is a diversified specialty pharmaceutical company focused on improving the lives of individuals with serious medical conditions, operating within the Pharmaceuticals sector and industry. Initially focused on abuse-deterrent products for chronic pain, Collegium has expanded its portfolio to include neuropsychiatry products, including Xtampza ER, Nucynta ER and IR, Belbuca, Symproic, and Jornay PM.

Collegium Pharmaceutical, Inc. primarily operates in the United States, where it commercializes its pain and neuropsychiatry portfolios. The company's corporate office is located in Stoughton, Massachusetts, United States. Collegium also has a presence in Canada through its subsidiary, Ironshore Therapeutics Inc.

Collegium Pharmaceutical, Inc. has maintained a positive brand reputation, emphasizing its commitment to responsible pain management and differentiated medications for serious medical conditions. The company actively participates in industry conferences and focuses on innovation, contributing to consistent industry recognition. A collaboration with Paris Hilton was initiated to raise awareness for ADHD and Jornay PM. No significant negative events impacting the company's reputation were reported during this period.

Collegium Pharmaceutical, Inc. has significant institutional ownership. As of September 2025, 241 institutional firms collectively held 117.3% of the company's total shares outstanding. Major institutional owners include BlackRock, Inc., Rubric Capital Management LP, and Vanguard Group Inc. Individuals hold 3.25% of the shares.